Clinical trials: Cyclophosphamide, completed
Neoplasms, Advanced
Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies
This is a Phase I dose escalation trial with escalating doses of Valproic acid and one dose escalation step of epirubicin. VPA will be escalated starting at a dose that is recommended for use as an anti-convulsant or to treat…
- Trial name
- NCT00246103
- Testing
- Valproic acid, Epirubicin, 5-fluorouracil
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Hematopoietic Stem Cell Transplantation
Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies
Mesenchymal stem cells (MSCs) have been used in the treatment and prevention of graft-versus host disease (GVHD). In this study the investigators aim to present the efficacy of mesenchymal stem cells in graft versus host disease…
- Trial name
- NCT03106662
- Testing
- mesenchymal stem cells, cyclophosphamide administration
- Where
- Turkey (Türkiye)
- Volunteers
- 6 people
- Sponsor
- Ankara University
Multiple Sclerosis
High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis
Multiple Sclerosis is a disease that may be caused by the immune system reacting against the nervous system. It is possible, that by changing the immune system we can modify the progression of this disease.
- Trial name
- NCT00040482
- Testing
- Cyclophosphamide, ATG, MESNA
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Baylor College of Medicine
Lung Cancer
Cisplatin, Etoposide, and Cyclophosphamide in Treating Patients With Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin, etoposide, and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00083161
- Testing
- cisplatin, cyclophosphamide, etoposide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Gundersen Lutheran Health System
Non-Hodgkin's Lymphoma, Hodgkin's Disease
Efficacy Study of Outpatient Therapy for Lymphoma
This is a Phase II trial evaluating the efficacy (overall response rate) of a risk-adjusted outpatient based approach to lymphoma salvage therapy with vinorelbine, gemcitabine and pegfilgrastim and/or gemcitabine, ifosfamide…
- Trial name
- NCT00163761
- Testing
- gemcitabine, vinorelbine, ifosfamide, filgastrim, gemcitabine, vinorelbine, filgastrim
- Where
- 10 sites in Australia
- Volunteers
- 90 people
- Sponsor
- Bayside Health
Brain and Central Nervous System Tumors
Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004224
- Testing
- cyclophosphamide, etoposide, vincristine sulfate
- Where
- 7 sites in Argentina, Canada and 5 more
- Volunteers
- 65 people
- Sponsor
- Societe Internationale d'Oncologie Pediatrique
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy before a donor bone marrow or stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00255710
- Testing
- filgrastim, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Non-Hodgkin's Lymphoma
Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma
About 60% of patients with DLBCL can be cured with a chemotherapy program. It is called RCHOP-21 (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone). It is given once every 3 weeks, for 18 weeks.
- Trial name
- NCT00712582
- Testing
- Etoposide, carboplatin, ifosfamide, Rituximab, Ifosfamide, Etoposide, Carboplatin, Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
This phase II trial is studying how well giving iodine I 131 tositumomab together with etoposide and cyclophosphamide followed by autologous stem cell transplant works in treating patients with relapsed or refractory…
- Conditions
- Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
- Trial name
- NCT00073918
- Testing
- cyclophosphamide, etoposide, iodine I 131 tositumomab
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Fred Hutchinson Cancer Center
Neuroblastoma, Bone Marrow, Sympathetic Nervous System
Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
Funding Source - FDA OOPD FDR004128 The goal of this study is to see if it is safe and feasible to give chemotherapy, natural killer (NK) cells, and an antibody called 3F8.
- Trial name
- NCT00877110
- Testing
- cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Myeloid Leukemia
Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML
In this multi-center, randomized, open-label, prospective clinical trial, a total of 60 relapsed/refractory AML patients will be randomized into 2 groups. In the experimental arm, patients receive IAC regimen.
- Trial name
- NCT02937662
- Testing
- Idarubicin, Cytarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Sclerosis, Chronic Progressive
Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis
Preliminary not-controlled clinical studies of the efficacy of monthly intravenous cyclophosphamide administration in secondary progressive multiple sclerosis reported encouraging results, but no randomized controlled trial has…
- Trial name
- PROMESS (NCT00241254)
- Testing
- Cyclophosphamide (drug), Methylprednisolone (drug)
- Where
- 26 sites in France
- Volunteers
- 138 people
- Sponsor
- University Hospital, Bordeaux
Neuroblastoma, Sarcoma
Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
The purpose of this study is to find out what effects, good and/or bad treatment with a new combination of drugs, cyclophosphamide, topotecan, and bevacizumab has on the patient and their cancer.
- Trial name
- NCT01492673
- Testing
- Cyclophosphamide, Topotecan, and Bevacizumab
- Where
- 7 sites in United States, Canada
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Neoadjuvant/Adjuvant Chemotherapy, Vaccine & Adjuvant Radiation Therapy in p53-Overexpressing Stage III Breast Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, work in different ways to stop tumor cells from dividing so…
- Trial name
- NCT00082641
- Testing
- autologous dendritic cell-adenovirus p53 vaccine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Nebraska
Adult Acute Lymphocytic Leukemia
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)
The study evaluates the efficacy and tolerability of a risk- and subtype-adapted chemotherapy over one year, followed by randomized either intensified or conventional maintenance therapy.
- Trial name
- NCT00199069
- Testing
- Asparaginase, Vincristine, Daunorubicin, Adriamycin
- Where
- Germany
- Volunteers
- 720 people
- Sponsor
- Goethe University
Chemotherapy Patients
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of YPEG-Filgrastim in Chemotherapy Patients
This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics of a single-dose of YPEG-Filgrastim in cancer patients receiving chemotherapy, and will establish dose-response relationships between…
- Trial name
- Filgrastim (NCT01238562)
- Testing
- YPEG-Filgrastim
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation
G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) appears to be an efficient tool to cure refractory anemia with excess blasts-1 (RAEB-1), refractory anemia with excess blasts-2 (RAEB-2) and acute myeloid leukemia…
- Conditions
- Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning
- Trial name
- NCT02744742
- Testing
- Decitabine, Busulfan (BU), Cyclophosphamide (CY)
- Where
- China
- Volunteers
- 202 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Breast Cancer, Nausea and Vomiting
Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer
RATIONALE: Antiemetic drugs, such as aprepitant, may help lessen or prevent nausea and vomiting in patients undergoing chemotherapy.
- Trial name
- NRR (NCT00719173)
- Testing
- aprepitant, cyclophosphamide
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Leukemia
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00008190
- Testing
- aldesleukin, filgrastim, busulfan
- Where
- United States
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia
CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies
This phase I clinical trial studies the side effects and best dose of CD19-specific T-cells in treating patients with lymphoid malignancies that have spread to other places in the body and usually cannot be cured or controlled…
- Conditions
- Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD19 Positive
- Trial name
- NCT02529813
- Testing
- Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.